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Abstract— The technologies for continuous measurement of
the anaesthetic agents circulating in body fluids are not mature
yet, though some preliminary prototypes exist already. We
present a control algorithm that based on the real measurement
of propofol plasma concentration may adjust the delivery
rate. This opens a possibility for a safer anesthesia when the
technologies for online measurement of drug concentration will
be mature enough to be combined with our model.
I. INTRODUCTION
The controlled delivery of intravenous anesthetics aims at
fast and safe achievement and maintenance of a certain depth
of hypnosis (DOH), correlated with the plasma concentration
of the administered drugs (e.g. propofol, fentanyl or midazo-
lam, etc.). Today, such drugs are regularly injected by Target
Controlled Infusion (TCI) systems, piloted by quantitative
predictions of plasma drug concentration based on phar-
macokinetic (PK) models complemented with an algorithm,
that based on the predicted output (e.g. drug concentration)
adjusts the drug delivery rate in an open-loop manner [11].
However, the inaccuracy of these models can reach up to 30-
50% [1] due to inter- and intra patients’ variability. Instead
of relying on drug concentration in plasma, some attempts to
improve the situation where made by introducing a closed-
loop control that uses the electroencephalogram (EEG) mon-
itoring to derive the bispectral index (BIS) associated to the
DOH [4]. However, BIS only indirectly depends on drug
delivery rate, is delayed with respect to the changes of drug
concentration in plasma, and can be affected by various
sources of noise, which can lead to overdosing or unexpected
awakening of a patient.
The situation can be improved by developing sensors for
continuous drug measurement in the blood that would be the
basis for a new closed-loop control. The classical closed-loop
controlling algorithm is the Proportional-Integral-Derivative
(PID) algorithm that is used to minimise the error of the
output variable of the physical part by computing the input
value as a weighted sum of this error. The error is computed
as a difference between the real measured and desired level
of the variable. The real measurement of the concentration of
anesthetic agents circulating in body fluids was not possible
until now, since there are no mature technologies yet, though
some preliminary prototypes exist already [3], [2]. However,
even when the technology will be mature enough, such
measurements will be affected by measurement noise and
will be delayed with respect to patients response. Therefore,
they will help only in narrowing down the inaccuracy of
the PK models. The further improvement will be made by
performing controlled delivery of anesthetics based on both
plasma drug concentration and DOH.
In this paper we present a closed-loop control algorithm
for the delivery of propofol, an anesthetic widely used for
general anesthesia. Currently, instead of the estimated plasma
concentration corrected with real measurements we directly
use the concentration values predicted by the population
PK and pharmacodynamic (PD) models [8] respectively. In
particular, in this paper we employ the Schnider [6], [7] PK
model, which allows us to compare the performance of our
closed-loop approach with the performance of the existing
Orchestrar BasePrimea TCI pump from Fresenius, widely
used in hospitals for general anesthesia delivery. Potentially,
the algorithm may simply control the plasma concentration;
it can also control the drug concentration at the effect site,
which in case of anesthetics is the brain, while keeping
plasma concentration within a limit. We present a cascaded
PID control algorithm that allows fast and safe achievement
of the target values of the effect site concentration while
keeping the plasma concentration within a limit. Neverthe-
less, it can be easily extended for the control of the level of
DOH. The performance of the algorithm when controlling
the effect site concentration is verified against the data from
the Orchestrar Base Primea TCI system from Fresenius.
The paper is organised as follows. Section II presents the
background on existing TCI pumps. Section III describes
the PK-PD models of propofol. In section IV we present the
control algorithm and evaluate its performance in section V.
II. TARGET CONTROLLED INFUSION OF ANAESTHESIA
Anesthetics are usually short-time acting, intravenously
administered drugs. They require an ensured multi-step gra-
dation of the effect intensity provided by the drug con-
centration in the blood. Therefore, anesthesiologists need
to continuously adjust the delivered rate in order to keep
the drug concentration at a certain level for an appropriate
degree of sedation and avoid both patient’s intoxication
and awareness. Propofol is a widely used anesthetic agent,
therefore the achievement and maintenance of its particular
concentration is of particular interest. Several software tools
computing the required delivery rate based on changes of
propofol concentration in blood has been developed in the
past: STANPUMP [10], IVASIM [9] and RUGLOOP [12].
Some of these algorithms have been commercialised.
One of the widely used TCI system for the delivery of
anesthetics and analgesics is the Orchestrar Base Primea
system from Fresenius. It consists of several identical mod-
ules, each one is designed to deliver: propofol, remifentanil
or sufentanil often given in cocktail during the surgery. The
independent modules of the TCI pump can control the drug
infusion based either on the plasma or effect site concentra-
tion that are predicted with one of the offered PK models.
For propofol delivery it is possible to choose either Marsh [5]
or Schnider [6], [7] models. While the parameters of the
PK models are openly available, the precise mechanism of
controlling the drug delivery rate is not presented in the
documentation but is a proprietary implementation of the
software tools mentioned above.
III. PK-PD MODELING
The PK of propofol is usually described by a three
compartment model extended with a virtual compartment
representing the effect site, which for anesthetic drug is
the brain. The PK-PD model for propofol is presented on
Figure 1. On the figure, the compartment with the volume V1
is the central compartment and represents the plasma of the
patient. The drug is delivered to the central compartment with
the delivery rate U and is cleared from it with elimination
rate k10. The two peripheral compartments with volumes V2
and V3 are the shallow and the deep compartments needed
to model the drug distribution and its further release into/by
various tissues, characterised by coefficients k12, k21, k13
and k31. The system of differential equations 1, 2 and 3
describes the change of drug concentrations in the three
compartments:
dC1
dt
= C2k21 + C3k31 − C1(k10 + k12 + k13) + U (1)
dC2
dt
= C1k12 − C2k21 (2)
dC3
dt
= C1k13 − C3k31 (3)
Fig. 1: 3 compartment PK-PD model
The estimated concentration of the drug at the effect site,
marked as a virtual compartment with the volume Veff , is
computed from the concentration in the central compartment
(transfer rate ke0) described by Eq. 4:
dCeff
dt
= (C1 − Ceff )ke0 (4)
It must be noted that the virtual compartment does not affect
the concentration in the central compartments, such that there
is not absorption or further release of the drug from/into
plasma. In this paper we will be using the parameters of the
Schnider model [6], [7].
The most right block on Figure 1 represents the PD part of
the model where E(Ceff ) stands for the level of the effect
that is the function of the effect site concentration Ceff .
E(Ceff ) is usually described with a Hill sigmoid [8]:
E(Ceff ) = E0 + (1− E0)
Cγeff
Cγeff,50 + C
γ
eff
(5)
where the value E = E0 ≈ 0 corresponds to the fully awake
state and E = 1 to total absence of cortical activity, Ceff,50
is the Ceff values that corresponds to 50% clinical effect and
γ > 1 is a parameter determining the shape of the sigmoid.
IV. CONTROL ALGORITHM
The controlled delivery of anaesthetics in general requires
the fast and safe achievement of certain DOH that depends on
the effect site concentration Ceff that transitively depends on
the plasma concentration of the drug C1. For the purposes of
the control problem presented further we will consider three
different scenarios for a control algorithm: (1) control of only
the plasma concentration C1 (control point γ1 on Figure 1);
(2) control of the effect site concentration Ceff , while
keeping the plasma concentration within a limit (control
point γ2); (3) control the BIS index while keeping the plasma
concentration within a limit (control point γ3). We propose
to use a classical PID controller for the above scenarios.
The currently existing TCI pumps, such as BasePrimea
from Fresenius, allow two modes of delivery, (1) and (2),
which we evaluate against our control algorithm in Sec-
tion V.
A. Classical PID controller
The PID control algorithm is used to minimise the error e
of the output variable of a physical system by computing
the input value I as a weighted sum of this error. The
error value is computed as a difference between the actual
measured output variable and desired level of that variable.
For digital implementation of the controller the weighted sum
is computed at every sampling instance tk as follows:
I(tk) = Kp ∗ e(tk−1) +Ki ∗ ei(tk−1) +Kd ∗ ed(tk−1) (6)
where Kp, Ki, Kd and e, ei, and ed are the proportional,
integral and derivative coefficients and errors respectively.
The error ep is simply the error of the output variable.
The computation for the derivative error ed requires the
implementation of the low pass filter to reduce the sensitivity
of the derivative term to random changes:
ed(tk) =
Td
Td +N∆t
[ed(tk−1)−KpN(e(tk)− e(tk−1))]
(7)
where N is the filter order, ∆t = tk−tk−1 and Td = Kd/Kp.
The integral error is computed as follows:
ei(tk+1) = ei(tk) +
Kp∆t
Ti
e(tk) +
∆t
Tf
es (8)
where the second term of the equation is used to memorise
the changes of the error e, while the third term is used
to prevent integration wind-up in PID controllers when
the actuator cannot provide the value v computed by the
controller due to the actuator physical limit at value u. This
way, es = v−u, while the integrator reset time Tf is chosen
between Ti and Td, where Ti = Kp/Ki and Td = Kd/Kp. In
this paper we choose the following value: Tf = (Ti+Td)/2.
B. Cascaded PID control
In case of scenario (1), when targeting the C1 concentra-
tion, it is enough to introduce one PID controller that based
on the error e = targetC1 − C1 will compute the required
delivery rate U . The second and the third scenarios are more
complicated: fast achievement of Ceff or DOH requires high
concentration C1, which at the same time, can not exceed a
certain level. Therefore, in order to be able to control two
points γ1 and γ2, or γ1 and γ3, we propose to use a cascaded
system of two PID controllers as shown on Figure 2.
Fig. 2: Cascaded PID control of PK-PD model
Essentially, the output of the first controller PID1 is the
target concentration in the central compartment targetC1
needed for fast and safe achievement of the target value at
the effect site targetPD based on the error e1 = targetPD−
PD. The output variable PD and its target value targetPD
can be either the predicted concentration at the effect site
Ceff and its target values targetCeff or the predicted effect
E(Ceff ) and the desired DOH level. The PID2 controller,
in turn, will be computing the actual drug delivery rate U
for fast and safe achievement of targetC1 value based on the
error e2 = targetC1−C1. Note that targetC1 is dynamically
changing. Such a structure allows a fast achievement of the
target concentration at the effect site while controlling the
drug concentration in plasma, so that it does not go over
certain level, which for Base Primea TCI pump is 15(mg/L).
Further we will present the case of scenario (2).
C. Tuning cascaded PID controller
It must be noted that we have more liberty in choosing the
coefficients of the external controller PID2 because there is
less restriction on safe achievement of the target value and
the physical system under control is described with a system
of differential equations 1–3 making it reluctant to input
changes. Thus, we choose the following coefficients: Kp2 =
100, Ki2 = 0.13, and Kd2 = 0.003. The value controlled by
the PID2 is the system input U that has upper and lower
limits for the delivery rate, 0 <= Ulim <= 200mg/min.
When any of the limits of the delivery rate is reached, the
third term of Eq. 8 will be computed with es = U − Ulim.
The internal controller PID1 of the cascade is much more
sensitive to parameter changes than the external one, where
the values of the proportional and integral coefficients are
playing a crucial role in controller performance and stability.
Both coefficients are directly proportional with the target val-
ues targetPD. It must also be noted that the targetPD value
may be changed during the infusion. The difference between
the new and the old target values J is inversely proportional
with the coefficients of PID1. We have developed a semi-
automatic coefficients tuning by providing a table of Kp1
and Ki1 values for ranges of targetPD and J .
We must also take into account that the input targetC1
computed by PID1 is the concentration of the central
compartment C1 that is limited 0 <= Clim <= 15mg/l.
When the upper limit is reached, we have to maintain the
concentration of the central compartment at this limit until
the computed value of targetC1 does not drop below this
limit. To achieve that, the delivery rate U of the drug (input
value of the PID2 controller) should be set to the value that
will maintain the current maximum allowed concentration of
the central compartment, meaning that dC1/dt = 0:
U = −C2k21 − C3k31 + C1(k10 + k12 + k13) (9)
where the values of C1, C2 and C3 are the drug concentration
values when the limit of C1 is achieved.
Also the value targetC1 can not be immediately pro-
vided, since the plasma concentration can be only gradually
achieved with a speed described by the PK model. We must
compensate the integral term according to the difference
between the value computed by the controller and the limit
value using es = targetC1 −C1 for the third term of Eq. 8.
The target concentration may be changed during the oper-
ation which will require the change of coefficients of PID1.
For the bumpless parameters change the integral term of
PID1 controller at each change must be adjusted as follows:
enewi = e
old
i + (K
old
p −Knewp )(targetPD − PD) (10)
V. EVALUATION
To validate our model we have performed several exper-
iments with the Base Primea pump without involving any
patient. We configured the pump with the parameters for
4 different imaginary patients: (1) a male of 36 years old,
with body weight 70kg and height 170cm; (2) a female of
25 years old with body weight 50kg and height 150cm;
(3) a male of 36 years old, with body weight 90kg and
height 170cm; and (4) a male of 65 years old, with body
weight 90kg and height 170cm. For each patient we have
performed 3 experiments by changing targets for the drug
concentrations at the effect site Ceff to: (exp. 1) 6, 4, 5 and
then to 0 mg/l; (exp. 2) 2, 3, 4, 5 and then to 0 mg/l; (exp.
3) 2, 4, 6 and then to 0 mg/l. The TCI data, i.e. the predicted
drug concentration for plasma and effect site and the delivery
rates, were loaded to the computer. Thus we could compare
them to the performance of our algorithm configured with
identical patient parameters and changes of target values.
Figure 3 presents the comparison of the results from our
algorithm with the values from TCI for the first patient
with the first experimental settings. The continuous lines
represent the values computed by our controller while the
dots correspond to the data collected from TCI pump. We
can see a good accordance between our algorithm and the
data of the TCI. Only when the target is decreased does our
model show more caution with respect to TCI.
Fig. 3: Achievement of targetCeff : Exp 1, Patient 1.
Figure 4 presents the comparison of the delivery rates
(mg/min, divided by 20 to better fit the graph) computed
by our model. It can be seen that our model computes the
delivery rates for initial shots higher than the TCI. However,
this shots are shorter in time compared to the TCI, which
makes the total amount of the drug delivered identical.
Fig. 4: Achievement of targetCeff : Exp 1, Patient 1.
VI. CONCLUSION
The existing open-loop solution can potentially adapt the
Bayesian approach for run-time individualisation of PK-PD
model parameters, with each new measurement. However,
this approach is not dealing with measurement noise, which
in case of BIS index can be quite large. The incorporation
of the PK model and real measurements is possible using
Kalman filter, which can be tuned to place either more
weight on the measurement or on the PK-PD model. Since,
it is not suitable to improve the existing open-loop solution,
the implementation of the closed-loop controller is required.
Therefore, the closed-loop control algorithm presented in
this paper represents a first step towards improvement of
precision of the TCI-based anesthesia. We choose the PID
algorithm rather than any higher order linear controller since
it is easier to tune and it already shows a good accordance
with the data from Base Primea TCI system. The cascaded
version provides modularity allowing to compose a specific
controller for each scenario described in Section IV. We have
run the experiments for 4 patients with parameter settings
covering extreme cases, provoking maximum variability in
PK model dynamics and our algorithm showed good stability.
Proving the algorithm robustness with more extreme cases
is certainly the next step in our future work.
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